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INTRODUCTION
Actual regulatory requirements by the European Medicines
Agency (EMA) (1) and the United States Pharmacopeia (USP)
(2) for elemental impurities monitoring in drug products
highlight the importance of analytical techniques able to
determine the concentration of these impurities in the ppm
range with a quantitative, fast and accurate analysis.
• CONCLUSIONS
WDXRF technique may be an alternative to the compendial
recommended analytical procedures;
• High levels of Cr, Mn and Pb were measured in some of the
analysed products;
• The simultaneous presence of high levels of Pb and Mn in
the same supplement, represent a concern to human
health, since both elements are neurotoxic;
• Humans are often exposed, by different routes and/or
sources, to toxic elements and supplementary consumption
of Dietary Supplements may cause potential toxicological
risks that cannot be ignored
• RESULTS
MATERIALS & METHODS
Equipment:
4 kW WDXRF spectrometer (S4 Pioneer, Bruker AXS).
Calibration and validation: According to ICH Guidelines (3).
Reagents: All reagents were of high analytical grade (≥99% Reagent or Ph
Eur).
Concentration ranges of calibration standards (ppm): 0-10 (Pb), 0-15 (Ir,
Os, Pt, Rh and Ru), 0-30 (Cr, Mo and Ni ) and 0-300 (Cu, Mn).
Samples:
WORK PURPOSES
• To investigated the feasibility of
WDXRF for the measurement of 11
elements (Cu, Cr, Ir, Mo, Mn, Ni, Os, Pb,
Pt, Rh and Ru) in drug products and
dietary supplements, following the
requirements set by international
bodies.
•To calculate Risk assessment for non-
carcinogenic effects for dietary
supplements using the Hazard Index (HI)
following the Environmental Protection
Agency (EPA) guidelines (4).
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High-density
polyethylene X ray 
fluorescence sample 
cups
Reduced to loose powder 
and homogenized in glass
mortars and pestles
3 powder samples 
5g each
Calibrated 4KW Commercial     
WDXRF Spectrometer (Bruker S4 
Pioneer)
• X ray tube with Rh anode and 
• 75 µm Be end window
• collimator aperture of 0.46° no 
filters 
• 34 mm diameter collimator mask
• measurements in helium mode
Sample
At least 6 concentration levels
were considered for each
element.
Samples: 27 drug products (6
branded, 21 generic) and 25
dietary supplements were
monitored (Figure 1).
Figure 2. Number of samples with impurities above USP limits
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Elemento <LQa Concentraçãob
(ppm)
EMAc limite 
(ppm)
>EMA 
limited
HQ 
(mediana)
HQ 
(máx)
Cr 22 42.54 (22.19; 63.12) 25 2 3.4E-4 5.0E-4
Mn 20 99.77 (66.63; 896.08) 250 1 8.5E-3 7.7E-2
Mo 17 7.13 (5.57; 10.44) 25 0 1.7E-2 2.5E-2
Os 22 2.84 (2.19; 3.39) 10 0 n.a n.a.
Pb 24 2.04 (1.74; 2.48) 1e 1f 6.8E-3 8.3E-3
Ru 12 14.33(10.06; 19.11) 10 13 n.a. n.a.
HI 3.3E-2 1.1E-1
Elemento <LQa Concentraçãob
(ppm)
EMAc limite
(ppm)
>EMA 
limited
HQ 
(mediana)
HQ 
(máx)
Ru 7 15.38 (10.05; 23.27) 10 20 n.a. n.a.
HI n.a. n.a.
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